Pharmigene, Inc.
7595
Rank in Stocks
#28117
Pharmigene, Inc. operates globally, specializing in the creation, production,... Pharmigene, Inc. operates globally, specializing in the creation, production, and distribution of diagnostic testing solutions. Its offerings include molecular diagnostic tools specifically designed to detect adverse drug reactions, alongside DNA extraction products crucial for diverse applications such as gene expression analysis, clinical molecular diagnostics, human identity verification, forensic investigations, and biomedical research. The firm also provides an array of specialized services, including pharmacogenomics, drug allergy screening, and functional medicine assessments. Beyond its own products, Pharmigene distributes various genomics and genetics equipment and reagents. Complementing these, it offers a comprehensive suite of support solutions, encompassing expert consultation, training programs, analytical software, and technical assistance. Furthermore, the company extends its capabilities through Contract Development and Manufacturing Organization (CDMO) services. Pharmigene, founded in 1994, is headquartered in Taipei, Taiwan.
Share Price
$0.24326598
Last synced: 2026-11-10
Market Cap
$12.28M
Change (1 day)
2.31%
Change (1 year)
-30.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharmigene, Inc. (7595)
Category
Healthcare
EPS for Pharmigene, Inc. (7595)
EPS as of June 2026 TTM: $-0.03
According to Pharmigene, Inc.'s latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $-0.05, equal to its 2024 EPS of $-0.05.
EPS history for Pharmigene, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.03 | -35.80% |
| 2025 | $-0.05 | -7.60% |
| 2024 | $-0.05 | -4.03% |
| 2023 | $-0.05 | 62.81% |
| 2022 | $-0.03 | 64.10% |
| 2021 | $-0.02 | 66.67% |
| 2020 | $-0.01 | -78.13% |
| 2019 | $-0.05 | 168.84% |
| 2018 | $-0.02 | 47.41% |
| 2017 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -20,353.58% |
DE
|
|
| $6.08 | -19,033.33% |
DE
|
|
| $1.55 | -4,930.53% |
JP
|
|
| $3.66 | -11,501.87% |
CH
|
|
| $0.45 | -1,501.87% |
IL
|
Questions about Pharmigene, Inc.'s earnings per share (EPS)
What is Pharmigene, Inc.'s earnings per share (EPS)?
Pharmigene, Inc.'s earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2026.
What was Pharmigene, Inc.'s earnings per share (EPS) in 2025?
In 2025, Pharmigene, Inc.'s earnings per share (EPS) was $-0.05, compared with $-0.05 in 2024.
How has Pharmigene, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pharmigene, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.01) and lowest in 2025 ($-0.05).
How does Pharmigene, Inc.'s earnings per share (EPS) compare with similar companies?
Pharmigene, Inc.'s earnings per share (EPS) ($-0.03) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.